Primary Central Nervous System Lymphoma (PCNSL)

Oncology

Prevalence

56.0 / 100K

Incidence

19.6 / 100K/yr

2 drugs in development·1 company·3 clinical trials

Drug Pipeline by Phase

Compare drugs

PD -1/PD-L1 monoclonal antibody vs Orelabrutinib

Frequently asked questions

How many drugs are in development for Primary Central Nervous System Lymphoma (PCNSL)?

BioSniper tracks 2 drugs in development for Primary Central Nervous System Lymphoma (PCNSL) across 1 company.

How many clinical trials target Primary Central Nervous System Lymphoma (PCNSL)?

There are 3 clinical trials targeting Primary Central Nervous System Lymphoma (PCNSL) tracked by BioSniper.

What is the prevalence of Primary Central Nervous System Lymphoma (PCNSL)?

The estimated prevalence of Primary Central Nervous System Lymphoma (PCNSL) is approximately 56.0 per 100,000 population.

Deep-dive into Primary Central Nervous System Lymphoma (PCNSL)

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Primary Central Nervous System Lymphoma (PCNSL) — Drugs in Development & Clinical Trials | BioSniper